Breakout Discussion:Effectively Managing Trial Execution and Preventing Overruns through Oversight and Governance Structure

By:
Posted: 05/08/2012

A recent Pharma IQ survey found that 43% don’t think their organisation effectively oversees clinical trial vendors, while 100% of those asked said they were feeling the pressure of increased regulatory scrutiny of vendor oversight.

So how do we balance effective trial oversight and governance without micromanaging and damaging the sponsor-vendor relationship?

Where do key performance metrics and milestones fit into the oversight strategy?

The 3rd Annual Global Clinical Outsourcing Forum, took place on the 24th-25th April 2012 in Amsterdam, bringing together 20 leading industry experts to guide you through the future of clinical partnerships and facilitate discussion on the issues that matter most to you.

Access key findings of the group work from Breakout Discussion: Effectively Managing Trial Execution and Preventing Overruns through Oversight and Governance Structure here.

Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

By:
Posted: 05/08/2012

Pharma IQ Members